Huons Global (084110) Fundamentals 2026 — P/E 12.2x, Revenue Analysis | SniperIQ
Huons Global (084110) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩290.5B, trading at ₩23800.00 on the KOE. This SniperIQ fundamentals page covers Huons Global's valuation (P/E 12.2x, P/B 0.5x), profitability (net margin 2.8%), revenue (₩847.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Huons Global's market cap?
Huons Global (084110) has a market capitalization of approximately ₩290.5B, trading at ₩23800.00 on the KOE. Market cap moves with the live share price.
What is Huons Global's P/E ratio?
Huons Global's trailing twelve-month P/E ratio is 12.2x, with a price-to-book (P/B) of 0.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Huons Global?
Huons Global runs a net profit margin of 2.8%, a gross margin of 46.5%, and an operating margin of 8.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Huons Global generate?
Huons Global reported revenue of ₩847.5B for fiscal year 2025, with net income of ₩28.8B and earnings per share (EPS) of 2366.77. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Huons Global pay a dividend?
Huons Global offers a trailing dividend yield of about 4.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Huons Global financially healthy?
Huons Global carries a debt-to-equity ratio of 0.53x and a current ratio of 1.80x, with a market beta of 0.03. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Huons Global a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Huons Global (084110) the key facts are: market cap ₩290.5B, P/E 12.2x, revenue ₩847.5B, 52-week range 22150-76700. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Huons Global's full fundamentals live
Get Huons Global's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.